{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:23:22Z","timestamp":1769009002462,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.advms.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T17:35:04Z","timestamp":1592242504000},"page":"316-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence"],"prefix":"10.1016","volume":"65","author":[{"given":"Bo\u017cena","family":"Cybulska-Stopa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Rogala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M.","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"\u0141ugowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Teterycz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Galus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Rajczykowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dawidowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Piejko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafa\u0142","family":"Suwi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2020.05.005_bib1","article-title":"Cutaneus melanomas","volume":"15","author":"Rutkowski","year":"2019","journal-title":"Oncol Clin Pract"},{"key":"10.1016\/j.advms.2020.05.005_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3389\/fimmu.2019.00990","article-title":"Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma","volume":"10","author":"Yu","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.advms.2020.05.005_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.advms.2014.12.002","article-title":"New therapeutic options for advanced non-resectable malignant melanoma","volume":"60","author":"Stadler","year":"2015","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.advms.2020.05.005_bib4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Canc Immunol Res"},{"key":"10.1016\/j.advms.2020.05.005_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.advms.2020.05.005_bib6","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.advms.2020.05.005_bib7","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.advms.2020.05.005_bib8","doi-asserted-by":"crossref","unstructured":"Maio M, Lebb\u00e9 C, Chiarion-Sileni V, Siegel J, Hoos A, Humphrey R, et al. Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg\/kg: ongoing analyses from completed Phase II trials. Ejc Supplements - EJC SUPPL. 7. 578-578. 10.1016\/S1359-6349(09)71951-2.","DOI":"10.1016\/S1359-6349(09)71951-2"},{"key":"10.1016\/j.advms.2020.05.005_bib9","series-title":"Congress\u2013perspectives in melanoma XIV, amsterdam, 2010","article-title":"Three-year survival rates for patients with advanced melanoma who received ipilimumab at 10 mg\/kg in Phase II Trials","author":"Maio","year":"2010"},{"key":"10.1016\/j.advms.2020.05.005_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2020.05.005_bib11","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.advms.2020.05.005_bib12","first-page":"231","article-title":"Ipilimumab \u2014 progress in therapy of advanced melanoma","volume":"7","author":"\u015awitaj","year":"2011","journal-title":"Onkol Prak Klin"},{"key":"10.1016\/j.advms.2020.05.005_bib13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2020.05.005_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger 2019","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.advms.2020.05.005_bib15","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2020.05.005_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.advms.2020.05.005_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2020.05.005_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.advms.2020.05.005_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"wsp. Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.advms.2020.05.005_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.advms.2020.05.005_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type Advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.advms.2020.05.005_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2020.05.005_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9503","article-title":"4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-na\u00efve advanced melanoma in KEYNOTE-006","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.advms.2020.05.005_bib24","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"S1470\u20132045","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.advms.2020.05.005_bib25","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.advms.2020.05.005_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2020.05.005_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.054","article-title":"Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)","volume":"29","author":"Hodi","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.advms.2020.05.005_bib28","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.advms.2020.05.005_bib29","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, Phase II trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.advms.2020.05.005_bib30","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.advms.2020.05.005_bib31","first-page":"118","article-title":"Outcomes in patients treated with ipilimumab after pembrolizumab in KEYNOTE-006","volume":"30","author":"Long","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.advms.2020.05.005_bib32","author":"Ministerstwo Zdrowia"},{"key":"10.1016\/j.advms.2020.05.005_bib33","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Canc 45(2): 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1016\/j.advms.2020.05.005_bib34","unstructured":"Common Terminology criteria for adverse events version 4.0) published: May 28, 2009 U.S. Department of Health and Human Services National Institutes of Health, National Cancer Institute."},{"issue":"2","key":"10.1016\/j.advms.2020.05.005_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/CMR.0000000000000221","article-title":"Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases","volume":"26","author":"Jacobsoone-Ulrich","year":"2016","journal-title":"Melanoma Res"},{"issue":"23","key":"10.1016\/j.advms.2020.05.005_bib36","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2217\/fon-2016-0037","article-title":"Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma","volume":"12","author":"Aya","year":"2016","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.advms.2020.05.005_bib37","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/bjc.2016.107","article-title":"Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy","volume":"114","author":"Bowyer","year":"2016","journal-title":"Br J Canc"},{"key":"10.1016\/j.advms.2020.05.005_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.10.009","article-title":"Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients","volume":"89","author":"Fujisawa","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.advms.2020.05.005_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Canc"},{"issue":"22","key":"10.1016\/j.advms.2020.05.005_bib40","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma\\ patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Canc Res"},{"issue":"6","key":"10.1016\/j.advms.2020.05.005_bib41","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA A Cancer J Clin"},{"issue":"3","key":"10.1016\/j.advms.2020.05.005_bib42","first-page":"257","article-title":"Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis","volume":"17","author":"Wiater","year":"2013","journal-title":"Contemp Oncol"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112620300225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112620300225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:40:57Z","timestamp":1761824457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112620300225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1896112620300225"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2020.05.005","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}